| No. cohorts | Incidence rate of adverse events (%) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) |
---|---|---|---|---|---|---|
Overall | 31 | 1.5 (1.4–1.6) | 100.0 |  < 0.001 |  | 100 |
Study population |  |  |  < 0.001 |  | ||
General population | 10 | 1.0 (0.9–1.0) | 100.0 |  < 0.001 |  | 98.92 |
Healthcare workers | 6 | 53.2 (28.4–77.9) | 99.8 |  < 0.001 |  | 0.80 |
Patients | 15 | 45.7 (33.8–57.6) | 97.2 |  < 0.001 |  | 0.28 |
Vaccine type |  |  |  < 0.001 |  | ||
BNT162b2 | 17 | 49.6 (21.8–77.4) | 99.9 |  < 0.001 |  | 23.57 |
AZD1222 | 4 | 79.6 (60.8–98.3) | 99.1 |  < 0.001 |  | 0.49 |
mRNA-1273 | 1 | 50.0 (34.9–65.1) | .. | .. |  | 0.01 |
CoronaVac | 3 | 30.8 (7.8–53.8) | 99.7 |  < 0.001 |  | 0.63 |
Ad26.COV2.S | 1 | 0.2 (0.2–0.2) | .. | .. |  | 25.03 |
Gam-COVID-Vac | 1 | 71.3 (67.9–74.7) | .. | .. |  | 0.08 |
BBIBP-CorV | 1 | 29.4 (24.8–34.0) | .. | .. |  | 0.04 |
Any | 3 | 0.0 (0.0–0.1) | 100.0 |  < 0.001 |  | 50.15 |
Population size |  |  |  < 0.001 |  | ||
 < 1000 | 24 | 57.6 (47.9–67.4) | 99.2 |  < 0.001 |  | 1.41 |
1000–10 000 | 3 | 29.1 (3.3–54.9) | 99.8 |  < 0.001 |  | 0.75 |
10 000–100 000 | 1 | 0.4 (0.3–0.4) | .. | .. |  | 22.74 |
 > 100 000 | 3 | 0.1 (0.0–0.1) | 100.0 |  < 0.001 |  | 75.11 |
 | No. cohorts | Incidence rate of severe adverse events (per 10 000) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) |
---|---|---|---|---|---|---|
Overall | 15 | 0.4 (0.2–0.5) | 98.2 |  < 0.001 |  | 100 |
Study population |  |  |  < 0.001 |  | ||
General population | 9 | 0.4 (0.2–0.5) | 98.9 |  < 0.001 |  | 84.53 |
Healthcare workers | 2 | 127.2 (62.7–191.8) | 36.1 | 0.211 |  | 0.01 |
Patients | 4 | 22.5 (0.0–72.6) | 77.7 | 0.004 |  | 15.46 |
Vaccine type |  |  |  < 0.001 |  | ||
BNT162b2 | 5 | 8.1 (0.0–17.8) | 98.2 |  < 0.001 |  | 7.71 |
mRNA-1273 | 2 | 4.2 (0.0–16.3) | 43.9 | 0.182 |  | 0.83 |
CoronaVac | 1 | 104.8 (53.7–156.0) | .. | .. |  | 0.01 |
Ad26.COV2.S | 1 | 0.4 (0.4–0.5) | .. | .. |  | 18.84 |
Gam-COVID-Vac | 1 | 175.7 (77.2–274.2) | .. | .. |  | 0.01 |
Any | 5 | 0.3 (0.2–0.5) | 99.1 |  < 0.001 |  | 72.60 |
Population size | Â | Â | 0.030 | Â | ||
 < 1000 | 4 | 90.4 (0.0–193.5) | 82.7 | 0.001 |  | 0.01 |
1000–10 000 | 3 | 336.6 (41.4–631.8) | 99.0 |  < 0.001 |  | 0.01 |
10 000–100 000 | 3 | 1.0 (0.0–2.2) | 73.3 | 0.024 |  | 8.54 |
 > 100 000 | 5 | 0.4 (0.2–0.5) | 99.2 |  < 0.001 |  | 91.45 |
 | No. cohorts | Incidence rate of death after vaccination (per 10 000) (95% CI) | I2 (%) | P value for heterogeneity | P value for subgroup differences | Weight (%) |
---|---|---|---|---|---|---|
Overall | 5 | 0.1 (0.1–0.2) | 87.6 |  < 0.001 |  | 100 |
Study population | Â | Â | 0.549 | Â | ||
General population | 3 | 0.1 (0.1–0.1) | 55.4 | 0.106 |  | 94.73 |
Patients | 2 | 7.6 (0.0–32.2) | 48.3 | 0.164 |  | 5.27 |
Vaccine type | Â | Â | 0.319 | Â | ||
BNT162b2 | 1 | 29.8 (0.0–71.2) | .. | .. |  | 0.01 |
Ad26.COV2.S | 1 | 0.1 (0.1–0.1) | .. | .. |  | 30.92 |
Any | 3 | 0.1 (0.1–0.2) | 92.4 |  < 0.001 |  | 69.07 |
Population size | Â | Â | 0.158 | Â | ||
 < 1000 | 1 | 29.8 (0.0–71.2) | .. | .. |  | 0.01 |
 > 100 000 | 4 | 0.1 (0.1–0.2) | 90.0 |  < 0.001 |  | 99.9 |